Share

Second breast cancers may be more difficult to treat in women who take the drug tamoxifen, study suggests

WHAT: Announcement of the results of a study, led by researchers at Seattle's Fred Hutchinson Cancer Research Center, to be published Wednesday in the Journal of the National Cancer Institute. The population-based study, involving data from nearly 9,000 breast-cancer patients in western Washington, looked at the impact of the drug tamoxifen on second breast cancers.

WHO: Christopher Li, M.D., a postdoctoral fellow in epidemiology at the Hutchinson Center, will present the study results and their implications.

WHEN: A news conference will be held at 2 p.m. Eastern. (11 a.m. Pacific) TODAY (Tuesday, July 3), which will be followed by a question-and-answer period.

WHERE: The news conference will be held at the Hutchinson Center's E. Donnall Thomas Clinical Research Laboratory Building, 1100 Fairview Ave. N., Seattle (the South Lake Union campus). A Media Relations representative will meet you in the lobby and escort you to the briefing room. Visitor parking is available in a lot outside the main entrance.

HOW TO DIAL IN TO TELECONFERENCE: Reporters unable to attend may participate in a simultaneous audio teleconference by calling 1-800-482-5519 about 10 minutes before the conference begins (1:50 p.m. Eastern/10:50 a.m. Pacific).

B-ROLL: Broadcast-quality beta B-roll of the drug tamoxifen and exteriors of the Hutchinson Center will be available to local broadcast media at the news conference. National media are requested to obtain this footage from their Seattle network affiliate.

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.